Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Clinical trial NCT03149029 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03149029
- Sponsor
- Massachusetts General Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-27
- Primary completion
- 2021-12-31
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.